other material
confidence high
sentiment positive
materiality 0.85
NTLA-2002 Phase 1 data: 95% mean HAE attack reduction; 9 of 10 patients attack free
Intellia Therapeutics, Inc.
- Single 25-75 mg dose of NTLA-2002 (n=10) produced 95% mean reduction in monthly HAE attack rate through median 9-month follow-up.
- All 9 patients achieving >60% plasma kallikrein reduction remain completely attack free since 16-week observation; longest attack-free interval 13.0 months.
- All 6 patients who discontinued long-term HAE prophylaxis after NTLA-2002 have reported no subsequent attacks.
- Safety: no dose-limiting toxicities, no serious adverse events, no Grade 3+ events; most adverse events mild and transient.
- Phase 2 portion of study now dosing; Intellia expects to complete enrollment in H2 2023.